文献速递肝病消化道肿瘤与早癌

靶向临床表观遗传重编程预防代谢性与病毒性肝细胞癌

Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
PubMed 文献 · Gut · 2020-03-26

该研究分析NASH和CHC患者肝组织的表观遗传与转录重编程,在细胞模型中鉴定染色质阅读器为靶点,并在NASH-HCC小鼠模型中验证溴结构域4抑制可抑制肝病进展和肝癌发生。

要点

  • CHC和NASH患者共享驱动肝癌风险的表观遗传与转录改变。
  • 染色质阅读器是逆转临床肝癌风险相关基因转录的潜在靶点。
  • 药物抑制染色质阅读器溴结构域4可抑制NASH-HCC小鼠肝病进展和肝癌发生。

核心结论

  • 代谢与病毒诱导的表观遗传改变对HCC发生具有功能相关性,染色质阅读器可作为慢性肝病患者化学预防的靶点。

研究设计与样本

  • 对NASH和CHC患者肝组织进行ChIP-Seq(H3K27ac)和RNA-Seq分析。
  • 在肝细胞培养系统中模拟患者肝病特异性表观遗传与转录重编程。
  • 结合扰动研究与靶向小分子筛选,并进行体内和离体验证。

主要发现

  • CHC和NASH患者共享相似的驱动癌症风险的表观遗传和转录组修饰。
  • 细胞模型鉴定染色质阅读器为逆转驱动临床HCC风险的肝脏基因转录的靶点。
  • NASH-HCC小鼠模型中药物抑制染色质阅读器溴结构域4可抑制肝病进展和肝癌发生。

临床怎么用

  • 染色质阅读器溴结构域4抑制可能作为慢性肝病患者的HCC化学预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hepatocellular carcinoma (HCC) is the fastest-growing cause of cancer-related mortality with chronic viral hepatitis and non-alcoholic steatohepatitis (NASH) as major aetiologies. Treatment options for HCC are unsatisfactory and chemopreventive approaches are absent. Chronic hepatitis C (CHC) results in epigenetic alterations driving HCC risk and persisting following cure. Here, we aimed to investigate epigenetic modifications as targets for liver cancer chemoprevention. DESIGN: Liver tissues from patients with NASH and CHC were analysed by ChIP-Seq (H3K27ac) and RNA-Seq. The liver disease-specific epigenetic and transcriptional reprogramming in patients was modelled in a liver cell culture system. Perturbation studies combined with a targeted small molecule screen followed by in vivo and ex vivo validation were used to identify chromatin modifiers and readers for HCC chemoprevention. RESULTS: In patients, CHC and NASH share similar epigenetic and transcriptomic modifications driving cancer risk. Using a cell-based system modelling epigenetic modifications in patients, we identified chromatin readers as targets to revert liver gene transcription driving clinical HCC risk. Proof-of-concept studies in a NASH-HCC mouse model showed that the pharmacological inhibition of chromatin reader bromodomain 4 inhibited liver disease progression and hepatocarcinogenesis by restoring transcriptional reprogramming of the genes that were epigenetically altered in patients. CONCLUSION: Our results unravel the functional relevance of metabolic and virus-induced epigenetic alterations for pathogenesis of HCC development and identify chromatin readers as targets for chemoprevention in patients with chronic liver diseases.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Jühling F, Hamdane N, Crouchet E, et al. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut. 2020. PMID: 32217639. doi:10.1136/gutjnl-2019-318918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。